The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Open accessAbstract
BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute hemodynamic responses of EPO administration may result in impaired perfusion/oxygen supply to the tissues and contribute to acute adverse events such as enhanced PLT aggregation, thromboembolism, and myocardial ischemia (17, 45).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationImpact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401
Research works printed but not linked: 8
- Pascual J, 1991, Clin Nephrol, 35, 280
- Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
- Collins A, 1994, J Am Soc Nephrol, 5, 439
- Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
- Barany P, 1996, J Am Soc Nephrol, 7, 1472
- Benz RL, 1996, J Am Soc Nephrol, 7, 1473
- Hoen B, 1995, Nephrol Dial Transplant, 10, 377
- Collins A, 1997, J Am Soc Nephrol, 8, 190A
Cited by
Sorted by citations
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,739
Metadata
- Authors
- Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
- Affiliations
- Henry Ford Hospital (US)
- University of Virginia Health System (US)
- Amgen (United States) (US)
- University of California, Los Angeles (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-08-27
- Volume
- 339
- Issue
- 9
- Pages
- 584-590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331665138
- Cited by
- 1,930
- References
- 28
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
